Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

Arrail Group (瑞尔集团) IPO Trading: Weak Demand, Rich Valuation

Arrail Group (瑞尔集团) Pre-IPO:  Peer Comp and Thoughts on Valuation

Arrail Group (瑞尔集团) Pre-IPO: Watch the Margins

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

<ul>
<li>Arrail is a leading premium dental service provider in China. The company launched book building to raise up to USD 87m via a Hong Kong listing.</li>
<li>In our previous notes, we looked at the company's background, its operation, its financials, and its expansion plan, and compared its key metrics with peers and provide thoughts on valuation.</li>
<li>In this note, we provide a quick update for the book building.</li>
</ul>


Arrail is a leading premium dental service provider in China. The company launched book building to raise up to USD 87m via a Hong Kong listing.
In our previous notes, we looked at the company's background, its operation, its financials, and its expansion plan, and compared its key metrics with peers and provide thoughts on valuation.
In this note, we provide a quick update for the book building.


Arrail Group (瑞尔集团) IPO: Downsized Deal Mostly Taken by Cornerstones